Artradol 100 mg/ml 2 ml 25 pcs. ampoules solution for intramuscular injection

Degenerative-dystrophic diseases of the joints and spine:
· osteoarthritis of peripheral joints;
· intervertebral osteochondrosis and osteoarthritis.
To accelerate the formation of callus in fractures.

Administer intramuscularly 100 mg (1 ml) every other day. With good tolerance, the dose is increased to 200 mg (2 ml), starting from the fourth injection.
The treatment course consists of 25-30 injections. If necessary, repeated courses may be conducted after 6 months.
For the formation of a bone callus, the treatment course lasts 3-4 weeks (10-14 injections every other day).

Composition per 1 ml:
Active ingredient:
Sodium chondroitin sulfate (calculated as 100% substance) - 100.0 mg;
Excipients: Sterile water for injection - up to 1.0 ml.

Clear, colorless or slightly yellowish liquid.

· Increased individual sensitivity to chondroitin sulfate;
· Bleeding, tendency to bleed;
· Thrombophlebitis;
· Age under 18 years (efficacy and safety not established).
With caution:
Simultaneous use of the drug with indirect anticoagulants, antiplatelet agents, fibrinolytics.

When used in conjunction with indirect anticoagulants, antiplatelet agents, and fibrinolytics, more frequent monitoring of blood coagulation parameters is required. In the event of allergic reactions or the appearance of hemorrhages, treatment should be discontinued.
To achieve a stable clinical effect, at least 25 injections of the drug are necessary. The effect persists for several months after the completion of the treatment course. To prevent exacerbations, repeated treatment courses are indicated.

Allergic reactions may occur (skin itching, rash, erythema, urticaria, dermatitis, edema); bleeding at the injection site. In these cases, the medication is discontinued.

Information on overdose is not available.

Possible enhancement of the action of indirect anticoagulants, antiplatelet agents, fibrinolytics.

Exhibits chondroprotective, regenerative, anti-inflammatory, and analgesic effects. Chondroitin sulfate is involved in the formation of the extracellular matrix of cartilage and bone tissue. It possesses chondroprotective properties, enhances metabolic processes in hyaline and fibrous cartilage, and subchondral bone; inhibits enzymes that cause degeneration (destruction) of articular cartilage; stimulates the production of proteoglycans by chondrocytes. It contributes to the reduction of the release of inflammatory mediators and pain factors into the synovial fluid, suppresses the secretion of leukotrienes and prostaglandins. It slows down the resorption of bone tissue and reduces calcium loss, accelerates the processes of bone tissue recovery.

Chondroitin sulfate slows the progression of osteoarthritis and osteochondrosis. It aids in the restoration of the joint capsule and articular surfaces of the joints, prevents the collapse of connective tissue, and normalizes the production of synovial fluid.

When using the product, tenderness decreases and mobility of the affected joints improves, with the therapeutic effect lasting for a long time after the end of the therapy course. In the treatment of degenerative changes in the joints accompanied by secondary synovitis, the effect is observed within 2-3 weeks from the start of the course.

Having structural similarity to heparin, it may potentially prevent the formation of fibrin clots in the synovial and subchondral microcirculatory pathways.

After intramuscular administration, it is detected in the blood in significant concentrations within 30 minutes; within 15 minutes - in the synovial fluid. The maximum concentration in plasma (Cmax) is reached after 1 hour, then the concentration of the drug gradually decreases over 2 days.
It accumulates mainly in cartilage tissue (the maximum concentration in articular cartilage is reached after 48 hours); the synovial membrane does not pose a barrier to the penetration of the drug into the joint cavity.
Excreted by the kidneys.